Gorlin Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Gorlin syndrome, also known as Gorlin-Goltz syndrome, nevoid basal cell carcinoma syndrome (BCNS), or basal cell nevus syndrome, is an autosomal dominant familial cancer syndrome. It manifests with numerous basal cell carcinomas (BCCs) and is accompanied by skeletal, ophthalmologic, and neurologic abnormalities. The syndrome gives rise to multiple neoplasms that initiate during childhood. The underlying cause of basal cell nevus syndrome is mutations within the patched (PTCH) gene. This gene encodes a transmembrane receptor responsible for recognizing sonic hedgehog signaling proteins. The syndrome demonstrates a high degree of penetrance while expressing variability in its presentation. Around 20% to 30% of BCNS cases are due to de novo mutations. Individuals harboring one mutated copy of the PTCH1 gene in each cell can exhibit Gorlin syndrome features early in life, including skeletal irregularities and macrocephaly. For basal cell carcinomas and other tumors to emerge, a mutation must also affect the second copy of the PTCH1 gene in specific cells during the person's lifetime. Individuals with one PTCH1 gene mutation will eventually acquire a second mutation in certain cells, ultimately developing diverse tumor types. Gorlin syndrome presents a range of symptoms and signals termed "indicators." These include:
1.
Basal cell carcinomas (BCCs) are a form of
skin cancer appearing on the face, hands, and back of the neck
2.
Odontogenic keratocystic tumors (OKCs) benign
cysts found in the jawbone
3.
Small depressions or pits on the palms of the
hands and the soles of the feet
Currently, there exists no specific
treatment or cure for Gorlin syndrome itself. Management of this syndrome
focuses on preventing, handling, and removing tumors and cysts stemming from
the condition. Various methods are available to eliminate the tumors and cysts
associated with Gorlin syndrome, such as cryotherapy (freezing), laser
treatments, and curettage (scraping).
·
Gorlin syndrome is a rare genetic disorder
that affects roughly 11,000 individuals in the United States.
Thelansis’s “Gorlin Syndrome Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Gorlin Syndrome treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Gorlin Syndrome across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Gorlin Syndrome Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment